spec sheet6 rows
Eptastigmine was the Italian pharmaceutical company Mediolanum's long-acting redesign of physostigmine, an old carbamate cholinesterase inhibitor whose natural form works but wears off too fast to dose conveniently; adding a heptyl (seven-carbon) chain extended its duration of action enough to make once- or twice-daily dosing plausible for Alzheimer's patients. It moved through a full decade of pharmacology, toxicology, and clinical study, including efficacy trials that showed genuine cognitive benefit over placebo. Then hematology data caught up with it, reversible neutropenia and, in a subset of patients, agranulocytosis (a dangerous collapse in infection-fighting white blood cells) showed up during clinical trials at a rate high enough that regulators would not accept the risk, and the program was discontinued despite a decade of otherwise promising work.
- longer duration of action than physostigmine, enabling more practical dosing schedules
- demonstrated cognitive efficacy versus placebo in Alzheimer's disease trials over roughly a decade of study
- reversible neutropenia reported in early trials (2 of 96 patients in one phase)
- agranulocytosis and granulocytopenia in a meaningful percentage of patients at higher/longer dosing (around 5-6% in one 4-week trial), the reason the drug was ultimately shelved
- Eptastigmine was studied for roughly ten years, pharmacology through clinical trials, before its hematologic safety profile finally ended the program, one of the longer development runs among the forgotten Alzheimer's cholinergics.
Mechanism
Reversible carbamate inhibitor of ; a long-chain heptyl derivative of physostigmine designed to extend that older drug's short duration of action while retaining its central cholinesterase-inhibiting activity.
Dosingtypical ranges, not medical advice
interested in protocols and clinical dosages? make an account to see them! ^_^
Safetyrisks and cautions, not medical advice
Blood counts, not the brain, ended this one. Across a programme covering more than 1,500 Alzheimer's patients the cholinergic effects were mild to moderate and no more frequent than placebo in the six-month trial, with 5 percent withdrawing for adverse events against 3 percent on placebo. Granulocytopenia in two studies, including agranulocytosis, is what suspended further trials, and it is not something an outpatient dementia population can be dose-adjusted around: it is a collapse in the white cells that fight infection and it arrives without warning. No blood-monitoring protocol was ever settled.
History
Developed by the Italian company Mediolanum Farmaceutici through roughly a decade of pharmacology, toxicology, and clinical trials for Alzheimer's disease; discontinued after hematologic adverse events, including agranulocytosis, emerged in a meaningful share of treated patients.
Subjective profileweighing the evidence above
A well-engineered fix for physostigmine's short half-life, sunk by a hematologic side effect nobody could risk-manage around.
Resources
This entry is here for reference.
Research
- 1.Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease
- 2.Eptastigmine: ten years of pharmacology, toxicology, pharmacokinetic, and clinical studies
2 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
What is eptastigmine chemically related to?
It is a heptyl (seven-carbon chain) derivative of physostigmine, an old natural carbamate cholinesterase inhibitor; the added chain was meant to extend physostigmine's short duration of action.
Why did eptastigmine get shelved despite showing efficacy?
Hematologic side effects, including cases of agranulocytosis, a dangerous drop in white blood cells that fight infection, showed up often enough during clinical trials that the safety risk outweighed the cognitive benefit.
Adverse effects
- reversible neutropenia reported in early trials (2 of 96 patients in one phase)
- agranulocytosis and granulocytopenia in a meaningful percentage of patients at higher/longer dosing (around 5-6% in one 4-week trial), the reason the drug was ultimately shelved